ERK signaling pathway in the effects of PPAR-γ agonist on Ang II-mediated KLF5 expression.

(A) VSMCs were subjected to ERK1/2 inhibitor PD098059 (1 μM) for 30min, followed by treatment of rosiglitazone (5 μM) for further 1 h, and finally stimulated with Ang II (0.1 mM) for 24 h. A representative western blot of KLF5 (upper panel), and data of mean ± S.E.M. of 3 experiments (bottom panel) were shown. (B) VSMCs were pretreated with rosiglitazone (5 μM) for 1h, and incubated with Ang II (0.1 μM) for 30 min, phosphorylated ERK1/2 were then detected by western blot. A representative western blot of ERK1/2 and p-ERK1/2, and data of mean ± S.E.M. of 3 experiments (bottom panel) were shown. Results are expressed as fold increase over control group. β-actin served as an internal control. (*P<0.05 vs. control; #P<0.05 vs. Ang II.)